Aprea Therapeutics, Inc. (APRE)
APRENASDAQ-CMBiotechnology: Pharmaceutical Preparations
$0.4531
+0.0131 (+2.98%) today
At the close, Nov 17, 4:00 PM ET. Pre-market $0.4577 +1.02%
- Market cap
- $6.50m
- P/E
- –
- EPS, last 4 quarters
- $-0.7000
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.4000 to $1.49
- Average volume
- –
- Previous close
- $0.4400
Analysts
4 coveringBuy4 buy, 0 hold, 0 sell
Targets a year out average $2.73, +502.5% from here
Earnings
next estimate $-0.1000Next report
Dec 2025
+15.8%
Mar 2026
+4.3%
Jun 2026
+68.2%
Sep 2026
-12.5%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $3,000 | – | – | – |
| Gross profit | $3,000 | – | – | – |
| Operating income | -$2.64m | -$3.43m | -$4.03m | -$5.17m |
| Net income | -$2.46m | -$3.29m | -$3.59m | -$4.81m |
News
8 latest- Aprea Q3 Loss Widens On R&D Costs; Updated APR-1051 Phase 1 Data Due November 20 RTTNews · Nov 5, 2026
- Aprea Therapeutics, Inc. Announces Third Quarter 2026 Financial ResultsFintel · Nov 4, 2026
- Aprea Expands Patent Portfolio For Precision Oncology Programs RTTNews · Aug 28, 2026
- Aprea Advances APR-1051; Phase 1 Enrollment Accelerates RTTNews · Aug 12, 2026
- Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue EstimatesZacks · Aug 6, 2026
- Aprea Therapeutics (APRE) Upgraded to Buy: Here's What You Should KnowZacks · May 21, 2026
- Oppenheimer Initiates Coverage of Aprea Therapeutics (APRE) with Outperform RecommendationFintel · May 7, 2026
- Aprea Therapeutics Closes Oversubscribed $30 Mln Private Placement; Stock Down RTTNews · Apr 2, 2026
The company
Aprea is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors but to minimize the effect on normal, healthy cells, decreasing the risk of toxicity that is frequently associated with chemotherapy and other treatments. Aprea's technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, colorectal, prostate, and breast cancers. The company's lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- aprea.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.